Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$0.38 -1.3%	$0.43	$0.22 ▼ $1.30	$3.99M	1	4.32 million shs	380,825 shs
HOTH Hoth Therapeutics	$1.25	$1.28	$0.59 ▼ $3.80	$16.51M	0.66	4.20 million shs	16,436 shs
LEXX Lexaria Bioscience	$0.86 +3.6%	$0.93	$0.79 ▼ $4.38	$16.82M	0.79	137,689 shs	6,768 shs
SYBX Synlogic	$1.49 +9.1%	$1.33	$0.90 ▼ $1.96	$17.37M	0.52	24,279 shs	9,613 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	-6.25%	-11.26%	+21.70%	-36.49%	-60.95%
HOTH Hoth Therapeutics	-5.30%	-6.02%	-3.85%	+31.22%	+111.90%
LEXX Lexaria Bioscience	-1.07%	-7.78%	-5.68%	-23.15%	-76.88%
SYBX Synlogic	-1.38%	-11.63%	+14.36%	+21.51%	-17.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	2.8399 of 5 stars	3.8	5.0	0.6	0.0	1.3
HOTH Hoth Therapeutics	2.9323 of 5 stars	3.6	5.0	2.5	0.0	0.6
LEXX Lexaria Bioscience	2.6361 of 5 stars	3.5	2.0	1.5	3.3	0.6
SYBX Synlogic	1.0046 of 5 stars	0.0	5.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	3.50	Strong Buy	$8.00	1,994.24% Upside
HOTH Hoth Therapeutics	3.25	Buy	$4.00	220.00% Upside
LEXX Lexaria Bioscience	3.00	Buy	$4.00	365.12% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ADIL, HOTH, SYBX, and LEXX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/29/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/1/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$0.64 per share	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
LEXX Lexaria Bioscience	$460K	36.57	N/A	N/A	$0.48 per share	1.79
SYBX Synlogic	$10K	1,737.45	N/A	N/A	$1.09 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$13.20M	-$1.46	N/A	N/A	N/A	N/A	-218.88%	-177.61%	8/12/2025 (Estimated)
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)
LEXX Lexaria Bioscience	-$5.80M	-$0.67	N/A	N/A	N/A	-1,849.19%	-157.22%	-133.69%	N/A
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	10.91%	7.47%	8/14/2025 (Estimated)

Latest ADIL, HOTH, SYBX, and LEXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SYBX Synlogic	-$0.13	N/A	N/A	N/A	N/A	N/A
8/12/2025	N/A	ADIL Adial Pharmaceuticals	-$0.25	N/A	N/A	N/A	N/A	N/A
8/8/2025	N/A	HOTH Hoth Therapeutics	-$0.27	N/A	N/A	N/A	N/A	N/A
7/14/2025	Q3 2025	LEXX Lexaria Bioscience	-$0.15	-$0.21	-$0.06	-$0.21	$0.17 million	$0.17 million
5/14/2025	Q1 2025	ADIL Adial Pharmaceuticals	-$0.50	-$0.34	+$0.16	-$0.34	N/A	N/A
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	1.99	1.99
HOTH Hoth Therapeutics	N/A	15.09	15.08
LEXX Lexaria Bioscience	N/A	3.90	3.90
SYBX Synlogic	N/A	3.68	3.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
HOTH Hoth Therapeutics	7.08%
LEXX Lexaria Bioscience	13.06%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	4.26%
HOTH Hoth Therapeutics	6.92%
LEXX Lexaria Bioscience	26.40%
SYBX Synlogic	3.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	10.44 million	9.99 million	No Data
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable
LEXX Lexaria Bioscience	7	19.56 million	14.40 million	Not Optionable
SYBX Synlogic	80	11.70 million	11.34 million	Optionable

ADIL, HOTH, SYBX, and LEXX Headlines

Recent News About These Companies

Synlogic (SYBX) Expected to Announce Quarterly Earnings on Thursday

August 7 at 2:46 AM | americanbankingnews.com

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

Synlogic Inc.

July 21, 2024 | wsj.com

Synlogic Inc SYBX

July 21, 2024 | morningstar.comM

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

May 23, 2024 | investorplace.com

Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties

May 16, 2024 | markets.businessinsider.com

SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | investorplace.com

Synlogic, Inc.: Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | finanznachrichten.de

Synlogic Flat on Q1 Numbers

May 14, 2024 | baystreet.ca

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL, HOTH, SYBX, and LEXX Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$0.38 -0.01 (-1.29%)

As of 10:26 AM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Hoth Therapeutics NASDAQ:HOTH

$1.25 0.00 (0.00%)

As of 10:21 AM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Lexaria Bioscience NASDAQ:LEXX

$0.86 +0.03 (+3.61%)

As of 10:26 AM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Synlogic NASDAQ:SYBX

$1.48 +0.12 (+9.12%)

As of 10:23 AM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time